The hypothesis that this proposal addresses is that high molecular weight kininogen (HMWK) on or about the platelet surface is an important regulator of plasma serine and cellular cysteine proteases. The objectives of this proposal are to identify and characterize the molecular interactions of HMWK with platelets. Studies will be performed to determine the mechanisms of interaction between HMWK and platelets or platelet constituents.
The specific aims of this proposal are (1) to characterize the availability of platelet HMWK expressed on the external membrane of activated platelets by monoclonal anti-HMWK125 I- Fab binding, immunocytochemical localization using colloidal gold, and molecular structure studies on activated platelet membranes as well as determine whether platelet HMWK can be a source of bradykinin for endothelial cell activation; (2) to investigate the interaction of exogenous HMWK with platelets to determine the molecular portion(s) of HMWK that binds to platelets, to identify the platelet receptor for HMWK, and to determine whether platelet-bound HMWK serves as a receptor for factors XI/XIa; (3) to study the interaction of HMWK with platelet calpain to determine the kinetics of HMWK's inhibition of platelet calpain, to characterize the domain(s) on HMWK that inhibit platelet calpain, to ascertain the mechanism of activation of HMWK by platelet calpain, and to determine whether platelet calpain liberates bradykinin from HMWK; and (4) to characterize the mechanism by which kallikrein inhibits platelet function and to ascertain the influence of HMWK on kallikrein's inhibition of platelet function. The proposed studies specifically address the molecular interactions of platelet and plasma HMWK on a physiologic surface. Since HMWK is a cofactor for activation of some serine zymogens (factor XII, prekallikrein, and factor XI) and an inhibitor of cysteine proteases (calpain and cathepsins) these studies will determine how HMWK associated with platelets can regulate these proteolytic systems. These studies on the interaction of HMWK with platelets should indicate new specific pathways by which the serine proteases, kallikrein and factor XIa, and cysteine proteases, calpains, could influence inflammation, intrinsic coagulation, fibrinolysis and blood pressure regulation.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Modified Research Career Development Award (K04)
Project #
Application #
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Temple University
Schools of Medicine
United States
Zip Code
Schmaier, A H (1997) Contact activation: a revision. Thromb Haemost 78:101-7
Heda, G D; Kehoe, K J; Mahdi, F et al. (1996) Phosphatase 2A participates in interferon-gamma's induced upregulation of C1 inhibitor mRNA expression. Blood 87:2831-8
Hasan, A A; Cines, D B; Ngaiza, J R et al. (1995) High-molecular-weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium. Blood 85:3134-43
Gluszko, P; Undas, A; Amenta, S et al. (1994) Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor. J Lab Clin Med 123:232-40
Schmaier, A H; Dahl, L D; Rozemuller, A J et al. (1993) Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa. J Clin Invest 92:2540-5
Zini, J M; Schmaier, A H; Cines, D B (1993) Bradykinin regulates the expression of kininogen binding sites on endothelial cells. Blood 81:2936-46
Jiang, Y; Nawarawong, W; Meloni, F J et al. (1992) Insights on monoclonal antibodies to kininogens' heavy chain which influence kininogens' binding to platelets. Thromb Haemost 68:143-8
Jiang, Y P; Muller-Esterl, W; Schmaier, A H (1992) Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J Biol Chem 267:3712-7
Jiang, Y P; Schmaier, A H (1992) Characterization of cell binding and thrombin inhibitory regions on kininogens' heavy chain. Agents Actions Suppl 38 ( Pt 1):233-40
Meloni, F J; Gustafson, E J; Schmaier, A H (1992) High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. Blood 79:1233-44

Showing the most recent 10 out of 24 publications